DK1694706T3 - Modificeret anti-CD52-antistof - Google Patents

Modificeret anti-CD52-antistof

Info

Publication number: DK1694706T3
Authority: DK; Denmark
Prior art keywords: antibody; modified anti; antibodies; expected; potential
Prior art date: 2003-11-01

Application number

DK04817412.2T

Other languages

English (en)

Inventor

Francis J Carr

Anita A Hamilton

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-11-01

Filing date

2004-10-29

Publication date

2012-07-16

2004-10-29 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2012-07-16 Application granted granted Critical

2012-07-16 Publication of DK1694706T3 publication Critical patent/DK1694706T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/467—Igs with modifications in the FR-residues only
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Oncology (AREA)
Hematology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK04817412.2T 2003-11-01 2004-10-29 Modificeret anti-CD52-antistof DK1694706T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51621003P	2003-11-01	2003-11-01
PCT/IB2004/003879 WO2005042581A2 (en)	2003-11-01	2004-10-29	Modified anti-cd52 antibody

Publications (1)

Publication Number	Publication Date
DK1694706T3 true DK1694706T3 (da)	2012-07-16

Family

ID=34549504

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04817412.2T DK1694706T3 (da)	2003-11-01	2004-10-29	Modificeret anti-CD52-antistof

Country Status (11)

Country	Link
US (3)	US7264806B2 (da)
EP (1)	EP1694706B1 (da)
JP (1)	JP4804357B2 (da)
CN (1)	CN1898267B (da)
AT (1)	ATE552276T1 (da)
BR (1)	BRPI0416141B8 (da)
CA (1)	CA2544365A1 (da)
DK (1)	DK1694706T3 (da)
ES (1)	ES2384105T3 (da)
PT (1)	PT1694706E (da)
WO (1)	WO2005042581A2 (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100056762A1 (en) *	2001-05-11	2010-03-04	Old Lloyd J	Specific binding proteins and uses thereof
AU2011202920C1 (en) *	2006-05-30	2012-11-15	Genentech, Inc.	Antibodies and immunoconjugates and uses therefor
US9498528B2 (en)	2006-09-13	2016-11-22	Genzyme Corporation	Treatment of multiple sclerosis (MS)
EP2167528B1 (en) *	2007-06-21	2018-01-10	Angelica Therapeutics, INC.	Modified toxins
US8470314B2 (en) *	2008-02-29	2013-06-25	Angelica Therapeutics, Inc.	Modified toxins
EP2411050A4 (en) *	2009-03-25	2013-07-17	Vet Therapeutics Inc	ANTIBODY REGIONS WITH A CONSTANT DOMAIN AND THEIR USE
MX2011012047A (es) *	2009-05-13	2011-12-14	Genzyme Corp	Inmunoglobulinas humanas anti-cd52.
RU2607022C2 (ru)	2009-05-13	2017-01-10	Джензим Корпорейшн	Способы и композиции для лечения волчанки
GB0914691D0 (en) *	2009-08-21	2009-09-30	Lonza Biologics Plc	Immunoglobulin variants
US9616120B2 (en) *	2010-03-04	2017-04-11	Vet Therapeutics, Inc.	Monoclonal antibodies directed to CD20
BR112012022342A2 (pt) *	2010-03-04	2017-02-14	Vet Therapeutics Inc	anticorpos monoclonais dirigidos a cd52
PE20140633A1 (es)	2010-11-19	2014-05-30	Eisai Randd Man Co Ltd	Anticuerpos neutralizadores anti-ccl20
WO2012161755A2 (en)	2011-02-02	2012-11-29	Emory University	Antagonism of the vip signaling pathway
GB201103955D0 (en)	2011-03-09	2011-04-20	Antitope Ltd	Antibodies
EP2696898A4 (en)	2011-04-07	2014-10-01	Univ Emory	COMPOSITIONS WITH SACCHARIDE-BINDING PARTS AND PROCEDURE FOR TARGETED THERAPY
GB201109238D0 (en) *	2011-06-01	2011-07-13	Antitope Ltd	Antibodies
EP3559049A4 (en)	2011-10-28	2019-12-04	Teva Pharmaceuticals Australia Pty Ltd	POLYPEPTIDE CONSTRUCTS AND APPLICATIONS THEREOF
AR095199A1 (es)	2013-03-15	2015-09-30	Genzyme Corp	Anticuerpos anti-cd52
EP3831840A1 (en) *	2013-03-15	2021-06-09	Celgene Corporation	Modified t lymphocytes
CA2902905A1 (en)	2013-03-15	2014-09-25	Claude Geoffrey Davis	Modified toxins
CA2908380A1 (en)	2013-04-09	2014-10-16	Boston Biomedical, Inc.	Methods for treating cancer
KR20230158134A (ko)	2014-10-14	2023-11-17	폴리테릭스 리미티드	Peg의 일부를 포함하는 이탈기를 포함하는 시약을 사용한, 펩티드 또는 단백질의 접합방법
CA2988126A1 (en)	2015-06-03	2016-12-08	Boston Biomedical, Inc.	Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
CA3045306A1 (en)	2016-11-29	2018-06-07	Boston Biomedical, Inc.	Naphthofuran derivatives, preparation, and methods of use thereof
EP3612563A1 (en)	2017-04-19	2020-02-26	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
US10646464B2 (en)	2017-05-17	2020-05-12	Boston Biomedical, Inc.	Methods for treating cancer
EP3720881A1 (en)	2017-12-08	2020-10-14	Elstar Therapeutics, Inc.	Multispecific molecules and uses thereof
WO2019209952A2 (en)	2018-04-23	2019-10-31	Emory University	Vip antagonists and uses in treating cancer
AU2019346645A1 (en)	2018-09-27	2021-04-29	Marengo Therapeutics, Inc.	CSF1R/CCR2 multispecific antibodies
CA3187272A1 (en)	2020-10-08	2022-04-14	Thorsten Ross	Trispecific binders
JP2024529381A (ja)	2021-07-30	2024-08-06	アフィメドゲーエムベーハー	デュプレックスボディ
AU2022382368A1 (en)	2021-11-03	2024-05-02	Affimed Gmbh	Bispecific cd16a binders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US6548640B1 (en) *	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5846534A (en) *	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
AU631545B2 (en)	1988-04-15	1992-12-03	Protein Design Labs, Inc.	Il-2 receptor-specific chimeric antibodies
KR100233781B1 (ko)	1989-11-06	1999-12-01	스테펜 에이. 쉐어윈	동종 재조합을 이용하는 단백질 제조방법
EP0438310A1 (en)	1990-01-19	1991-07-24	Merck & Co. Inc.	Method for producing recombinant immunoglobuline
GB9014932D0 (en) *	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
GB9125768D0 (en) *	1991-12-04	1992-02-05	Hale Geoffrey	Therapeutic method
CU22615A1 (es) *	1994-06-30	2000-02-10	Centro Inmunologia Molecular	Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US5846543A (en)	1995-10-24	1998-12-08	Hassler; Mark A.	Bovine mastitis treatment
ATE319745T1 (de)	1997-05-21	2006-03-15	Biovation Ltd	Verfahren zur herstellung von nicht-immunogenen proteinen
GB9712892D0 (en)	1997-06-20	1997-08-20	Eclagen Ltd	Identification of mhc binding peptides
US6835550B1 (en) *	1998-04-15	2004-12-28	Genencor International, Inc.	Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
AU776910B2 (en)	1998-12-08	2004-09-23	Merck Patent Gesellschaft Mit Beschrankter Haftung	Modifying protein immunogenicity
JP4334866B2 (ja) *	2000-10-09	2009-09-30	アイシスイノヴェイションリミテッド	治療用抗体
ATE400030T1 (de) *	2001-02-19	2008-07-15	Merck Patent Gmbh	Methode zur identifizierung von t-zellepitopen und deren anwendung zur herstellung von molekülen mit reduzierter immunogenität
MXPA04004417A (es) *	2001-11-12	2004-08-11	Merck Patent Gmbh	Anticuerpo anti-tnf alfa modificado.
US20030157641A1 (en) *	2001-11-16	2003-08-21	Idec Pharmaceuticals Corporation	Polycistronic expression of antibodies

2004
- 2004-10-29 AT AT04817412T patent/ATE552276T1/de active
- 2004-10-29 EP EP04817412A patent/EP1694706B1/en not_active Expired - Lifetime
- 2004-10-29 DK DK04817412.2T patent/DK1694706T3/da active
- 2004-10-29 CN CN200480036043XA patent/CN1898267B/zh not_active Expired - Lifetime
- 2004-10-29 BR BRPI0416141A patent/BRPI0416141B8/pt active IP Right Grant
- 2004-10-29 JP JP2006537487A patent/JP4804357B2/ja not_active Expired - Fee Related
- 2004-10-29 WO PCT/IB2004/003879 patent/WO2005042581A2/en active Application Filing
- 2004-10-29 ES ES04817412T patent/ES2384105T3/es not_active Expired - Lifetime
- 2004-10-29 US US10/977,369 patent/US7264806B2/en not_active Expired - Lifetime
- 2004-10-29 CA CA002544365A patent/CA2544365A1/en not_active Abandoned
- 2004-10-29 PT PT04817412T patent/PT1694706E/pt unknown
2007
- 2007-08-03 US US11/833,818 patent/US7910104B2/en not_active Expired - Lifetime
- 2007-10-31 US US11/932,086 patent/US20080248529A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PT1694706E (pt)	2012-06-19
BRPI0416141A (pt)	2007-01-02
JP2007534304A (ja)	2007-11-29
US20080248529A1 (en)	2008-10-09
US20080075715A1 (en)	2008-03-27
CN1898267A (zh)	2007-01-17
US7264806B2 (en)	2007-09-04
US7910104B2 (en)	2011-03-22
BRPI0416141B8 (pt)	2021-05-25
CA2544365A1 (en)	2005-05-12
WO2005042581A2 (en)	2005-05-12
JP4804357B2 (ja)	2011-11-02
EP1694706A2 (en)	2006-08-30
ES2384105T3 (es)	2012-06-29
WO2005042581A8 (en)	2006-06-29
WO2005042581A3 (en)	2005-07-28
EP1694706B1 (en)	2012-04-04
US20050152898A1 (en)	2005-07-14
CN1898267B (zh)	2012-05-23
ATE552276T1 (de)	2012-04-15
BRPI0416141B1 (pt)	2019-01-15

Publication	Publication Date	Title
DK1694706T3 (da)	2012-07-16	Modificeret anti-CD52-antistof
CY1121208T1 (el)	2020-05-29	Σκευασματα αντισωματος ναταλιζουμαμπης
CY1116632T1 (el)	2017-03-15	Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου
TW200745161A (en)	2007-12-16	Stable antibody formulation
DE602006006200D1 (de)	2009-05-20	Antikörper gegen 25-hydroxyvitamin d
TR201901841T4 (tr)	2019-03-21	Her antikorlarının sabit dozlaması.
PE20140806A1 (es)	2014-07-17	Anticuerpos anti-factor d humanizados y sus usos
CY1118343T1 (el)	2017-06-28	Αντισωματα συνδεσης twεακ
UA92505C2 (ru)	2010-11-10	Композиции на основе антитела против cd3
IL244803A0 (en)	2016-04-21	Human anti-beta7 antibodies and their use
EA200802170A1 (ru)	2009-06-30	Лиофилизированная композиция терапевтического пептидного антитела
GT200500298A (es)	2006-05-08	Formulaciones de anticuerpos
CR10530A (es)	2009-01-29	Anticuerpos anti-dlla4 y metodos que los usan
DK1937721T3 (da)	2010-10-18	Anti-IL-23 antistoffer
NO20083895L (no)	2008-10-24	Anti-IGF-1R human monoklonalantibody formulering
TW200714290A (en)	2007-04-16	Anti-M-CSF antibody compositions having reduced levels of endotoxin
MA35009B1 (fr)	2014-04-03	Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
CR10555A (es)	2009-04-29	Vacunas para malaria
CO6270369A2 (es)	2011-04-20	Nuevos anticuerpos especificos de los peptidos beta -amiloides y sus usos como agentes de diagnostico o drogas
EA200801174A1 (ru)	2009-02-27	Антитела-миметики glp-2, полипептиды, композиции, способы и применения
NO20084320L (no)	2008-12-16	Antistoffer mot EGFL7 og fremgangsmater for anvendelse av disse
EA200800601A1 (ru)	2009-08-28	Связывающие fas антитела
MA46988A1 (fr)	2020-06-30	Formulation liquide d'anticorps anti-tnf alpha
GT201300058A (es)	2014-07-16	Composiciones de anticuerpos anti-vegfr-3
UA94211C2 (ru)	2011-04-26	Выделенное полностью человеческое моноклональное cd3 антитело